Actively Recruiting
Angiopoietin and Adverse Outcomes in Cardiac Surgery
Led by Centre Hospitalier Universitaire, Amiens · Updated on 2025-05-25
200
Participants Needed
1
Research Sites
210 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cardiac surgery and cardiopulmonary bypass can lead to systemic organ failure trough excess inflammation and endothelial injury. The angiopoietin family represented by angiopoietin 1 and 2 can reflect endothelial injury by a decrease in angiopoietin 1 and an increase in angiopoietin 2. The investigators hypothesized that angiopoietin dysregulation could reflect organ failure related to cardiac surgery. The purpose of this project is to assess the association between angiopoietin dysregulation and adverse outcomes on cardiac surgery.
CONDITIONS
Official Title
Angiopoietin and Adverse Outcomes in Cardiac Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient scheduled for cardiac surgery under cardiopulmonary bypass
You will not qualify if you...
- Patient less than 18 years old
- Redo surgery
- Urgent surgery
- Endocarditis
- Aortic root repair surgery
- Aortic dissection
- Heart beating surgery
- Heart transplantation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU Amiens Picardie
Amiens, France
Actively Recruiting
Research Team
O
Osama ABOU ARAB, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here